comparemela.com
Home
Live Updates
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate : comparemela.com
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer models Initiating IND-enabling studies with goal...
Related Keywords
Massachusetts ,
United States ,
Boston ,
San Francisco ,
California ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Davidc Myles ,
Geoffrey Mogilner ,
Nasdaq ,
Clinical Development ,
Securities Exchange ,
Olema Pharmaceuticals Inc ,
Exchange Commission ,
International Conference On Molecular ,
Drug Administration ,
Chief Discovery ,
Non Clinical Development Officer ,
Molecular Targets ,
Cancer Therapeutics ,
Investigational New Drug ,
Securities Act ,
Securities Exchange Act ,
Quarterly Report ,
Vice President ,
Investor Relations ,
Markets ,
comparemela.com © 2020. All Rights Reserved.